Compounds and compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-10196403-B2
Application number	US-201715663688-A
Country	US
Kind code	B2
Filing date	Jul 28, 2017
Priority date	Jul 29, 2016
Publication date	Feb 5, 2019
Grant date	Feb 5, 2019

Abstract

Disclosed are compounds of formula (I):

and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

First claim

The invention claimed is:

1. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

2. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

3. A method of treating a neurological or psychiatric disease or disorder selected from bipolar disorder, anxiety, depression, Alzheimer's Disease with agitation, Alzheimer's Disease with aggression or Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound selected from:

or a pharmaceutically acceptable salt thereof.

4. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

5. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

6. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

7. A method of treating Alzheimer's Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of treating Alzheimer's Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

9. A method of treating Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

10. The compound according to claim 2 , wherein said compound is greater than 90% enantiomerically pure.

11. The compound according to claim 2 , wherein said compound is greater than 95% enantiomerically pure.

12. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

13. The compound according to claim 12 , wherein said compound is greater than 90% enantiomerically pure.

14. The compound according to claim 12 , wherein said compound is greater than 95% enantiomerically pure.

15. A compound, wherein said compound is:

or a pharmaceutically acceptable salt thereof.

16. The compound according to claim 15 , wherein said compound is greater than 90% enantiomerically pure.

17. The compound according to claim 15 , wherein said compound is greater than 95% enantiomerically pure.

18. A compound, wherein said compound is:

19. The compound according to claim 18 , wherein said compound is greater than 90% enantiomerically pure.

20. The compound according to claim 18 , wherein said compound is greater than 95% enantiomerically pure.

21. A compound, wherein said compound is:

22. The compound according to claim 21 , wherein said compound is greater than 90% enantiomerically pure.

23. The compound according to claim 21 , wherein said compound is greater than 95% enantiomerically pure.

24. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

25. A pharmaceutical composition comprising the compound according to claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

26. A pharmaceutical composition comprising the compound according to claim 12 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

27. A pharmaceutical composition comprising the compound according to claim 15 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

28. A pharmaceutical composition comprising the compound according to claim 18 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

29. A pharmaceutical composition comprising the compound according to claim 21 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

30. A method of treating Alzheimer's Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

31. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

32. A method of treating anxiety in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

33. A method of treating depression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

34. A method of treating Alzheimer's Disease in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

35. A method of treating Alzheimer's Disease with agitation in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

36. A method of treating Alzheimer's Disease with aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

37. A method of treating Alzheimer's Disease with agitation aggression in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 12 , or a pharmaceutically acceptable salt thereof.

38. A method of treating bipolar disorder in a subject in need thereof, comprising administering to said subject an effective amount of the compound according to claim 15 , or a pharmaceutically acceptable salt thereof.

39. A method of treating anxiety in a subject

Assignees

• Sunovion Pharmaceuticals Inc
• Pgi Drug Discovery Llc

Inventors

• Hanania Taleen G
• Heffernan Michele L R
• Jones Philip Glyn
• Xie Linghong

Classifications

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• C07D313/08

  condensed with one six-membered ring · CPC title

• C07D311/76 Primary

  Benzo[c]pyrans · CPC title